Patient with agammaglobulinemia produces anti-SARS-CoV-2 reactive T-cells after CoronaVac vaccine

Clinics (Sao Paulo). 2022 Feb 2:77:100007. doi: 10.1016/j.clinsp.2022.100007. eCollection 2022.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Agammaglobulinemia*
  • COVID-19*
  • Humans
  • SARS-CoV-2
  • T-Lymphocytes
  • Vaccines*

Substances

  • Vaccines